Tag: BD
Lutonix AV global registry shows higher target lesion primary patency when...
In a new post-hoc analysis of the Lutonix (BD) arteriovenous (AV) global registry using investigational device exemption (IDE) criteria, Dimitrios Karnabatidis (Patras University Hospital,...
Rotarex™S: A 25-year legacy continues
This advertorial, sponsored by BD, is only available in selected countries and geographies.
This year marks a significant milestone as BD celebrates 25 years...
BD announces first patient enrolled in PAD vascular covered stent trial
BD has announced the enrolment of the first patient in the AGILITY investigational device exemption (IDE) study, which will assess the safety and effectiveness...
BD launches vascular access ultrasound system
BD, a leading global medical technology company, have launched a new advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted...
Venous Summit 2023: Holistic, multidisciplinary approach to venous care is “mandatory”
This advertorial, sponsored by BD, is intended only for readers outside the USA.
“A dedicated, holistic venous approach is mandatory—including deep, superficial and pelvic venous...
Promising future previewed for PAD treatment at Riga summit
This advertorial is sponsored by BD.
There has been major progress in the treatment of peripheral arterial disease (PAD) globally in the last few years,...
ESKD Summit 2023: What matters to patients gains momentum with input...
This advertorial is sponsored by BD.
Focusing on the disease through the patient’s lens, establishing well-functioning multidisciplinary teams, to potentially enhance both the patient’s journey...
Multidisciplinary community unites at inaugural patient-focused ESKD Summit
This advertorial, sponsored by BD, is only available in selected countries and geographies.
“The Changing Face of a Dialysis Patient” was the central theme...
BD launches first-in-human trial of a peripheral sirolimus drug-coated balloon
BD has announced the start of enrolment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB).
The PREVISION trial is a prospective, multicentre,...
AVeVA study confirms benefit of covered stent placement in graft-vein anastomotic...
A prospective, multicentre study involving the Covera vascular covered stent (BD) has confirmed the benefits of immediate, post-percutaneous transluminal angioplasty (PTA) placement of the...
Interventional News’ top 10 most popular items of January 2022
January’s top 10 features technological advancements, with Cook Medical receiving US Food and Drug Administration (FDA) approval for new drug-eluting stents and Adept Medical...
Interventional News’ top 10 most popular items of January 2022
January’s top 10 features technological advancements, with Cook Medical receiving US Food and Drug Administration (FDA) approval for new drug-eluting stents and Adept Medical...
BD launches Crosser iQ CTO recanalisation system
BD (Becton, Dickinson and Company) has announced the launch and 510(k) clearance from the US Food and Drug Administration (FDA) of the Crosser iQ...
Minimally-invasive, outpatient WavelinQ offers an alternative to open surgery
NOTE: This video is ONLY available to watch in selected countries and geographies
This advertorial is sponsored by BD. This advertorial is part of...
Treating the dysfunctional vascular access: The expert’s low-pressure, low-dose approach
NOTE: This advertorial is ONLY available to watch in selected countries and geographies
This is advertorial sponsored by BD.
Panagiotis M Kitrou (Patras University Hospital, Patras,...
BD announces 510(k) clearance of expanded indications for the Rotarex atherectomy...
BD recently announced it has received 510(k) clearance for expanded indications from the US Food and Drug Administration (FDA) for the Rotarex atherectomy system.
The...
The WavelinQ™ EndoAVF System takes an innovative approach in creating endovascular...
This advertorial is ONLY available to watch in selected countries and geographies
This advertorial, sponsored by BD, is intended for readers in the EMEA...
Why Rotarex is my first choice treatment in patients with bypass...
NOTE: This video is ONLY available to watch in selected countries and geographies
Bruno Migliara (Peschiera del Garda, Italy) talks to Vascular News about the reasons...
Case report: Recanalisation of a long SFA occlusion with Ultrascore™ Focused...
This advertorial, sponsored by BD, is intended for healthcare professionals in Europe only.
“Improving vessel compliance with focused force longitudinal plaque fracture seems to be...
BD announces enrolment in postmarket studies of the WavelinQ endoAVF system
BD announced today that enrolment has begun and the first patients have been treated in the postmarket surveillance study, CONNECT-AV.
CONNECT-AV is a prospective, single-arm,...
Case report: Complex endovascular treatment for an iliac artery occlusion using...
This advertorial, sponsored by BD, is only available in selected countries and geographies.
Martin Schroeder—a vascular surgery specialist at the Ruhr University Bochum Marienhospital...
FDA advisory panel recommends against premarket approval of Lutonix 014 DCB...
A US Food and Drug Administration (FDA) advisory panel has recommended against premarket approval of BD’s Lutonix 014 drug-coated balloon (DCB) for use in...
CLEAN3 trial outlines potential new best practices for peripheral IV catheters
BD today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring...
Ellipsys system offers greater patient eligibility and reduced time to dialysis,...
Two devices for creating minimally invasive dialysis access—the Ellipsys vascular access system (Avenu Medical) and the WavelinQ 4F system (BD)—demonstrated high rates of technical...
24-month AVeNEW study results: Covered stent angioplasty “statistically superior” to angioplasty...
Against the backdrop of increasing end-stage renal disease (ESRD) prevalence in the USA, Bart Dolmatch (Portola Valley, USA) presented the 24-month results of the...
BD announces launch of Halo One thin-walled guiding sheath
BD has announced the launch of the Halo One thin-walled guiding sheath, designed to perform as both a guiding sheath and an introducer sheath,...
Straub Medical acquired by BD
Straub Medical has approved a full acquisition by Becton, Dickinson and Company (BD). The acquisition was completed on 20 April 2020. Straub Medical manufactures,...
Caterpillar embolization devices gain FDA clearance
The Caterpillar and Caterpillar Micro arterial embolization devices (BD) have received US Food and Drug Administration (FDA) clearance.
The Caterpillar devices utilise a novel dual...
LINC 2020: BD announces long-term safety data for BTK drug-coated balloon
Today at the 2020 Leipzig Interventional Course (LINC; 28–31 January, Leipzig, Germany), BD announced that interim findings from the Lutonix below-the-knee (BTK) investigational...
BIBA Briefings: FDA approval of IN.PACT AV is a boon for...
Last month (November), the FDA approved Medtronic’s paclitaxel-coated balloon IN.PACT AV for the management of failing arteriovenous fistulae (AVF). Approval for the device was based...
BD announces publication of drug-coated balloon safety data for femoropopliteal PAD
BD has announced the publication of a company-initiated, independent analysis of the Lutonix 035 drug-coated balloon (DCB) femoropopliteal clinical programme in the Journal of...
FDA notifies BD that Lutonix paclitaxel balloon PMA application for below...
The US Food and Drug Administration (FDA) have denied BD premarket approval (PMA) for the company’s Lutonix drug-coated balloon (DCB) in the treatment of...
BD receives FDA approval for expansion to drug-coated balloon product line
The US Food and Drug Administration (FDA) has approved expanded sizes of the Lutonix 018 drug-coated balloon (DCB) to treat long superficial femoral artery...
BD announces launch of UltraScore 014 Focused Force PTA Balloon
BD has announced the launch of their UltraScore 014 Focused Force percutaneous transluminal angioplasty (PTA) Balloon. This marks the first scoring balloon with sheath...
BD receives FDA 510(k) clearance of WavelinQ 4F endoAVF system
BD has announced the 510(k) clearance from the US Food and Drug Administration (FDA) for the WavelinQ 4F endoAVF system earlier this month. The endoAVF...
BD’s Lutonix 018 DCB approved by FDA to treat SFA disease
The FDA has granted approval for BD’s 0.018-inch guidewire-compatible Lutonix 018 drug-coated balloon (DCB) for the treatment of long superficial femoral artery lesions in...
CASE REPORT: SFA-CTO Recanalization by using the novel 0.035″ ULTRASCORE Focused...
This case report is sponsored by BD.
Ralf Langhoff, chief, Angiology/Vascular Medicine, Sankt Gertrauden-Krankenhaus, Berlin, Germany, reports on a case in which his team used...
Lutonix BTK randomised trial meets safety and efficacy endpoints at six...
Six-month outcomes of a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (BD; DCB) has demonstrated the DCB is safe to use...
BD acquires TVA Medical, makers of everlinQ endoAVF System
BD (Becton, Dickinson and Company) announced it has completed the acquisition of TVA Medical, a company that develops minimally invasive vascular access solutions...
New products showcased at SIR 2018
There were several devices in the New Product Showcase at the Society of Interventional Radiology's Annual Scientific Meeting in Los Angeles, USA. Among these...
EU Mergers Commission approves acquisition of Bard by BD
The European Commission, under the EU Merger Regulation, has approved the acquisition of Bard by BD, subject to conditions. Both US-based companies supply medical...
BD to acquire Bard for US$24 billion
BD (Becton, Dickinson and company) has definitively agreed to acquire Bard for US$317 per common share in cash and stock, for a total consideration...
UK Medical announces ‘strategic buy out’ from BD
A Sheffield healthcare company has announced a strategic ‘buy out’ from its parent company, BD (Becton, Dickinson and Company), a deal which will see...